Synonym
PD-173212; PD 173212; PD173212;
IUPAC/Chemical Name
(S)-N-((S)-1-amino-3-(4-(benzyloxy)phenyl)-1-oxopropan-2-yl)-N-(tert-butyl)-2-((4-(tert-butyl)benzyl)(methyl)amino)-4-methylpentanamide
InChi Key
WJAVQCPRFGVNSN-HEVIKAOCSA-N
InChi Code
InChI=1S/C38H53N3O3/c1-27(2)23-34(40(9)25-29-15-19-31(20-16-29)37(3,4)5)36(43)41(38(6,7)8)33(35(39)42)24-28-17-21-32(22-18-28)44-26-30-13-11-10-12-14-30/h10-22,27,33-34H,23-26H2,1-9H3,(H2,39,42)/t33-,34-/m0/s1
SMILES Code
O=C(N)[C@H](CC1=CC=C(OCC2=CC=CC=C2)C=C1)N(C([C@H](CC(C)C)N(CC3=CC=C(C(C)(C)C)C=C3)C)=O)C(C)(C)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Biological target:
PD173212 is a selective N-type voltage sensitive calcium channel (VSCC) blocker, with an IC50 of 36 nM in IMR-32 assays.
In vitro activity:
In the process of searching for small molecule N-type calcium channel blockers, this study has identified a series of N-methyl-N-aralkyl-peptidylamines with potent functional activity at N-type VSCCs. The most active compound discovered in this series is PD 173212 (11, IC50 = 36 nM in the IMR-32 assays).
Reference: Bioorg Med Chem Lett. 1999 Aug 2;9(15):2151-6. https://pubmed.ncbi.nlm.nih.gov/10465535/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
100.0 |
166.71 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
599.86
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
Hu LY, Ryder TR, Rafferty MF, Dooley DJ, Geer JJ, Lotarski SM, Miljanich GP, Millerman E, Rock DM, Stoehr SJ, Szoke BG, Taylor CP, Vartanian MG. Structure-activity relationship of N-methyl-N-aralkyl-peptidylamines as novel N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2151-6. doi: 10.1016/s0960-894x(99)00359-5. PMID: 10465535.
In vitro protocol:
Hu LY, Ryder TR, Rafferty MF, Dooley DJ, Geer JJ, Lotarski SM, Miljanich GP, Millerman E, Rock DM, Stoehr SJ, Szoke BG, Taylor CP, Vartanian MG. Structure-activity relationship of N-methyl-N-aralkyl-peptidylamines as novel N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2151-6. doi: 10.1016/s0960-894x(99)00359-5. PMID: 10465535.
1: Hu LY, Ryder TR, Rafferty MF, Dooley DJ, Geer JJ, Lotarski SM, Miljanich GP, Millerman E, Rock DM, Stoehr SJ, Szoke BG, Taylor CP, Vartanian MG. Structure-activity relationship of N-methyl-N-aralkyl-peptidylamines as novel N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2151-6. PubMed PMID: 10465535.
2: Ryder TR, Hu LY, Rafferty MF, Millerman E, Szoke BG, Tarczy-Hornoch K. Multiple parallel synthesis of N,N-dialkyldipeptidylamines as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1813-8. PubMed PMID: 10406647.
3: Coppi E, Cherchi F, Fusco I, Failli P, Vona A, Dettori I, Gaviano L, Lucarini E, Jacobson KA, Tosh DK, Salvemini D, Ghelardini C, Pedata F, Di Cesare Mannelli L, Pugliese AM. Adenosine A3 receptor activation inhibits pronociceptive N-type Ca2+ currents and cell excitability in dorsal root ganglion neurons. Pain. 2019 May;160(5):1103-1118. doi: 10.1097/j.pain.0000000000001488. PMID: 31008816; PMCID: PMC6669900.
4: Dong Y, Gao Y, Xu S, Wang Y, Yu Z, Li Y, Li B, Yuan T, Yang B, Zhang XC, Jiang D, Huang Z, Zhao Y. Closed-state inactivation and pore-blocker modulation mechanisms of human CaV2.2. Cell Rep. 2021 Nov 2;37(5):109931. doi: 10.1016/j.celrep.2021.109931. PMID: 34731621.
